Antiangiogenic treatment as a pre-operative management of alveolar soft-part sarcoma

Pediatr Blood Cancer. 2011 Dec 1;57(6):1071-3. doi: 10.1002/pbc.23241. Epub 2011 Jul 9.

Abstract

Alveolar soft-part sarcoma (ASPS) is a rare tumor. Cure is based solely on radical surgery. The general prognosis is poor. The tongue is an unusual site in adults, but not in children. Tumor removal can cause a severe impact on quality of life, even if reconstruction is possible. ASPS is a highly vascularized tumor and antiangiogenic therapy may have a role. We describe the use of the antiangiogenic combination bevacizumab and celecoxib in the preoperative management of a patient with an ASPS of the tongue.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Bevacizumab
  • Celecoxib
  • Child, Preschool
  • Female
  • Humans
  • Neovascularization, Pathologic / diagnosis
  • Neovascularization, Pathologic / drug therapy*
  • Pyrazoles / therapeutic use
  • Quality of Life
  • Sarcoma, Alveolar Soft Part / diagnosis
  • Sarcoma, Alveolar Soft Part / drug therapy*
  • Sarcoma, Alveolar Soft Part / surgery
  • Sulfonamides / therapeutic use
  • Tongue Neoplasms / diagnosis
  • Tongue Neoplasms / drug therapy*
  • Tongue Neoplasms / surgery
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Pyrazoles
  • Sulfonamides
  • Bevacizumab
  • Celecoxib